<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pathobiology of follicular lymphoma</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pathobiology of follicular lymphoma</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Pathobiology of follicular lymphoma</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer R Brown, MD, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Arnold S Freedman, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jon C Aster, MD, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Andrew Lister, MD, FRCP, FRCPath, FRCR</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rebecca F Connor, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jun 06, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H26243868"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Follicular lymphoma (FL) is the second most common subtype of non-Hodgkin lymphoma. It is defined as a lymphoma of germinal center B cells, and virtually always demonstrates a growth pattern that is partially follicular. (See  <a class="medical medical_review" href="/z/d/html/4716.html" rel="external">"Classification of hematopoietic neoplasms"</a>.)</p><p>The molecular pathogenesis of FL is a complex, multistep process during which a single follicular B cell acquires all of the genetic and epigenetic alterations needed for malignant transformation. The resultant tumor is usually comprised of a mixture of centrocytes (small cleaved germinal center cells) and centroblasts (large noncleaved germinal center cells). Some common steps in this pathway have been elucidated, particularly chromosomal rearrangements involving BCL-2 and certain somatic mutations, some of which are also seen in other non-Hodgkin lymphomas. In the not uncommon instance in which FL evolves into a more aggressive lymphoma, usually diffuse large B cell lymphoma, the molecular lesions found early in the disease course persist and are found along with additional new acquired mutations that contribute to histologic transformation. (See  <a class="medical medical_review" href="/z/d/html/4724.html" rel="external">"Histologic transformation of follicular lymphoma"</a>.)</p><p>This review will discuss the pathobiology of FL in adults. Of note, pediatric follicular lymphoma is a different form of FL that mainly develops in children and adolescents, but is also seen in young adults, and has distinctive clinical and pathologic features. The epidemiology, clinical presentation, pathologic features, diagnosis, treatment, and prognosis of FL are discussed separately. General aspects of the pathobiology of non-Hodgkin lymphoma are also discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4699.html" rel="external">"Clinical manifestations, pathologic features, diagnosis, and prognosis of follicular lymphoma"</a> and  <a class="medical medical_review" href="/z/d/html/4741.html" rel="external">"Initial treatment of stage I follicular lymphoma"</a> and  <a class="medical medical_review" href="/z/d/html/4755.html" rel="external">"Treatment of relapsed or refractory follicular lymphoma"</a> and  <a class="medical medical_review" href="/z/d/html/4711.html" rel="external">"Overview of the pathobiology of the non-Hodgkin lymphomas"</a>.)</p><p class="headingAnchor" id="H26244312"><span class="h1">CELL OF ORIGIN</span><span class="headingEndMark"> — </span>FL is a heterogeneous clinicopathologic entity that has as a common feature an origin from germinal center B cells [<a href="#rid1">1</a>]. The tumor is comprised of variable numbers of small, cleaved cells (centrocytes) and larger, blastoid cells (centroblasts) that morphologically resemble cells found in the light and dark zones of normal germinal centers, respectively. The germinal center ancestry of these cells is principally supported by the identification of somatic mutations in the variable region of the immunoglobulin genes (IgVH), which serves as a marker of germinal center transit [<a href="#rid2">2</a>], the follicular growth pattern of the tumor cells in most cases, and the immunophenotype of the tumor cells, which in most respects closely resembles that of normal germinal center B cells. (See  <a class="medical medical_review" href="/z/d/html/4711.html" rel="external">"Overview of the pathobiology of the non-Hodgkin lymphomas", section on 'B cell lymphoma'</a>.)</p><p class="headingAnchor" id="H91137362"><span class="h1">PATHOGENESIS</span></p><p class="headingAnchor" id="H91137370"><span class="h2">Overview</span><span class="headingEndMark"> — </span>The development of the majority of FL tumors in adults is dependent on the overexpression of B cell leukemia/lymphoma 2 (BCL-2) located on chromosome band 18q21. BCL-2 is an oncogene that blocks programmed cell death (apoptosis). As such, overexpression results in increased cell survival. BCL-2 overexpression in itself is not sufficient for FL development and other genetic lesions or host factors are required  (<a class="graphic graphic_figure graphicRef56311" href="/z/d/graphic/56311.html" rel="external">figure 1</a>). (See <a class="local">'Other genetic lesions'</a> below.)</p><p>BCL-2 overexpression is virtually always the result of a translocation that places the <em>BCL-2</em> gene under the control of immunoglobulin promoter/enhancer elements. Of these, the t(14;18)(q32;q21) is most common and places <em>BCL-2</em> under the control of the IgH locus, but variant translocations also occur that place <em>BCL-2</em> under the control of the kappa or lambda immunoglobulin loci instead. (See <a class="local">'Translocations involving BCL-2'</a> below.)</p><p>These aberrations likely represent mistakes that occur during attempted antigen receptor gene diversification in normal B cells. In the bone marrow, pre-B cells rearrange the V(D)J segments of their immunoglobulin (Ig) loci to allow expression of IgM. This process, termed V(D)J recombination, requires the recombination activating genes RAG1 and RAG2. Subsequently, in the germinal center, antigen stimulated B cells undergo class-switch recombination (from IgM to IgG, IgA, or IgE) and somatic hypermutation. Somatic hypermutation, a key component of the humoral immune response, is the process by which point mutations and small deletions or insertions are introduced at high frequency into the variable regions of immunoglobulin heavy chain genes. Both class switch recombination and somatic hypermutation require the enzyme activation-induced cytidine deaminase (AID).</p><p>The sequences found immediately adjacent to the points of DNA breakage and rejoining in <em>BCL-2</em>/Ig translocations implicate RAG1/RAG2 in the process [<a href="#rid3">3</a>]. It remains uncertain whether these RAG mediated breaks occur in pre-B cells or during antigen receptor gene "editing" in germinal center B cells. Cells bearing such rearrangements gain a selective advantage when the consequence is overexpression of an oncogene such as <em>BCL-2</em>. AID-mediated class-switching and somatic hypermutation are also error-prone, and it is strongly suspected that additional AID-dependent mutations introduced by these processes in germinal center B cells contribute to the development of FL. (See  <a class="medical medical_review" href="/z/d/html/4711.html" rel="external">"Overview of the pathobiology of the non-Hodgkin lymphomas", section on 'Chromosomal translocations'</a>.) </p><p>Since FL often shows evidence of ongoing somatic hypermutation, it is possible that AID contributes to acquisition of additional mutations that are involved in histologic transformation of FL as well. (See  <a class="medical medical_review" href="/z/d/html/4724.html" rel="external">"Histologic transformation of follicular lymphoma"</a>.)</p><p class="headingAnchor" id="H26244320"><span class="h2">Aberrant BCL-2 expression</span></p><p class="headingAnchor" id="H91137600"><span class="h3">BCL-2 action</span><span class="headingEndMark"> — </span>The B cell leukemia/lymphoma 2 (<em>BCL-2</em>) gene encodes a 26-kDa integral membrane protein localized to the outer mitochondrial membrane and endoplasmic reticulum [<a href="#rid4">4</a>]. BCL-2 has little or no ability to promote cell cycle progression or cell proliferation, but rather raises the cellular apoptotic threshold, thereby inhibiting apoptosis (programmed cell death). Normally in germinal center B cells, BCL-2 expression is restricted to cells that through the process of somatic hypermutation, by chance, acquire Ig with high affinity for antigen; these cells are thought to then emerge from germinal centers as long-surviving memory B cells [<a href="#rid4">4</a>] or to differentiate into plasma cells. This hypothesis is supported by data from mice bearing <em>BCL-2</em> transgenes that show markedly protracted secondary immune responses and an extended lifetime for memory B cells in the absence of antigen [<a href="#rid5">5,6</a>].</p><p>Apoptosis (programmed cell death) is essential for normal embryonic development, maintenance of tissue homeostasis, and development and function of the immune system. In contrast, processes that interfere with normal apoptosis promote cell survival and, potentially, oncogenesis. Apoptosis is regulated by a balance of pro-apoptotic factors and anti-apoptotic factors [<a href="#rid7">7</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Pro-apoptotic factors – Two categories of pro-apoptotic factors exist, one consisting of multi-domain proteins (eg, BAX and BAK), and the second consisting of single BH3-domain only proteins (eg, BAD and BID). BAX and BAK are the major initiators of apoptosis. How BH3-domain only proteins promote apoptosis is unsettled; they may contribute by inhibiting anti-apoptotic proteins (see below) or by directly activating BAX. Once activated, BAX and BAK form aggregates in the mitochondrial membrane that promote apoptosis by releasing cytochrome c from the mitochondria into the cytoplasm, leading to the activation of caspase-9 followed by caspase-3, a so-called apoptotic executioner. Active caspase-3 proteolyzes a number of key cellular proteins, including a negative regulatory unit of caspase activated DNase, an endonuclease that cleaves DNA and contributes to apoptosis [<a href="#rid8">8-10</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Anti-apoptotic factors – BCL-2, BCL-XL and MCL-1 are examples of anti-apoptotic factors. These anti-apoptotic factors restrain the activity of pro-apoptotic proteins, such as BAX and BAK, and prevent the release of mitochondrial proteins, such as cytochrome c, thereby inhibiting apoptosis.</p><p></p><p>FL demonstrates increased expression of the anti-apoptotic factors (BCL-2, BCL-XL, and MCL1) and very low or undetectable amounts of pro-apoptotic factors such as BAX and BAD [<a href="#rid11">11,12</a>]. This imbalance promotes cell survival.</p><p>How <em>BCL-2</em> translocations contribute to the development of FL is complex and incompletely understood. It has long been known that <em>BCL-2</em>/IgH translocations can be detected at low frequency (ie, one cell in 1000 to one cell in 10,000) in the germinal centers of a high fraction of normal individuals, almost none of whom will go on to develop FL [<a href="#rid13">13,14</a>]. Similarly, highly sensitive methods can detect the t(14;18) at low levels in the peripheral blood of some healthy individuals [<a href="#rid15">15,16</a>]. One study found that these (14;18) translocations are found within a population of atypical germinal center-type B cells that have phenotypic features of FL [<a href="#rid17">17</a>]. These observations clearly indicate that <em>BCL-2</em>/IgH translocations are not sufficient to cause FL, and that other genetic or epigenetic events are rate limiting for its development.</p><p>The natural history of persons with low levels of circulating clones resembling FL is not known. In one study, a highly sensitive PCR-based assay was able to identify IgH/<em>BCL-2</em> fusion genes in a subset of patients up to 15 years before diagnosis of FL [<a href="#rid18">18</a>]. While not all patients with the translocation developed FL, and not all patients who developed FL had the translocation in pre-diagnostic blood samples, samples from those who went on to develop FL were more likely to be positive (56 versus 29 percent).</p><p class="headingAnchor" id="H26243875"><span class="h3">Translocations involving BCL-2</span><span class="headingEndMark"> — </span>In the vast majority of cases, FL is associated with a translocation between the long arm of chromosome 18, the site of the <em>BCL-2</em> oncogene (18q21), and one of three loci containing immunoglobulin (Ig) genes [<a href="#rid19">19,20</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>The Ig heavy chain gene on chromosome 14 – Resulting in the t(14;18)(q32;q21) found in approximately 85 percent of FL.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The kappa light chain gene on chromosome 2 – Resulting in the t(2;18)(p11;q21), which is uncommon but considered a biologic equivalent.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The lambda light chain gene on chromosome 22 – Resulting in the t(18;22)(q21;q21), which is uncommon but considered a biologic equivalent.</p><p></p><p>The consequence of these translocations is the presence within the cells of constitutively high levels of BCL-2 protein, resulting from both enhanced transcription and, possibly, more efficient RNA processing  (<a class="graphic graphic_picture graphicRef64808" href="/z/d/graphic/64808.html" rel="external">picture 1</a>) [<a href="#rid21">21,22</a>].</p><p class="headingAnchor" id="H174935843"><span class="h2">BCL-2 negative cases</span><span class="headingEndMark"> — </span>Less than 10 percent of FLs lack <em>BCL-2</em> translocations, and in these tumors BCL-2 protein expression is decreased relative to <em>BCL-2</em> translocation-positive cases or absent altogether [<a href="#rid23">23</a>]. These tumors often fall into one of two morphologic subgroups: </p><p class="bulletIndent1"><span class="glyph">●</span>Predominantly diffuse follicular lymphoma</p><p class="bulletIndent1"><span class="glyph">●</span>Tumors with a follicular growth pattern and grade 3b cytologic features </p><p></p><p>Predominantly diffuse follicular lymphoma differs from typical FL in showing variable BCL-2 protein expression, strong expression of CD23, frequent deletions involving chromosome 1p36, and mutations in <em>TNFRSF14</em>, a gene encoding a member of the tumor necrosis factor (TNF) family [<a href="#rid24">24,25</a>]. It often presents as a localized mass in the inguinal region and is recognized as a distinct subtype of FL in the World Health Organization (WHO) classification of lymphoid neoplasms [<a href="#rid1">1</a>]. </p><p>In grade 3b FL sheets of centroblasts grow in a follicular pattern [<a href="#rid26">26</a>]. (See  <a class="medical medical_review" href="/z/d/html/4699.html" rel="external">"Clinical manifestations, pathologic features, diagnosis, and prognosis of follicular lymphoma", section on 'Grade'</a>.)</p><p>The clinical course of grade 3b FL is generally more similar to that of diffuse large B cell lymphoma (DLBCL) than that of FL grades 1 and 2. One study using cytogenetics demonstrated that this morphologic subgroup includes [<a href="#rid27">27</a>]: </p><p class="bulletIndent1"><span class="glyph">●</span>Tumors with the t(14;18) affecting <em>BCL-2</em> </p><p class="bulletIndent1"><span class="glyph">●</span>Tumors with 3q27 rearrangements affecting <em>BCL-6</em></p><p class="bulletIndent1"><span class="glyph">●</span>Tumors that lack either of these characteristic cytogenetic abnormalities</p><p></p><p>The same molecular subdivisions exist in DLBCL, leading to the suggestion that grade 3b FL with the t(14;18) is more similar to FL grades 1 and 2, while the other two cytogenetic subtypes are more closely related to de novo DLBCL [<a href="#rid27">27</a>]. Although this series suggested that <em>BCL-6</em> rearrangements and <em>BCL-2</em> rearrangements are mutually exclusive in FL, subsequent studies have identified rare tumors with both rearrangements [<a href="#rid28">28</a>]. In either case, BCL-6 expression may play a role in the pathogenesis of a subset of grade 3b FL. <em>BCL-6</em> encodes a transcription factor that is essential for normal germinal center B cell development. Expression of BCL-6 in normal germinal center B cells down-regulates genes that sense DNA damage, such as the p53 tumor suppressor gene, which would otherwise trigger apoptosis in response to the physiologic DNA rearrangements of the germinal center, and also inhibits terminal B cell differentiation. This is described in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/4722.html" rel="external">"Pathobiology of diffuse large B cell lymphoma and primary mediastinal large B cell lymphoma", section on 'Aberrant BCL6 expression'</a>.)</p><p class="headingAnchor" id="H26244328"><span class="h2">Other mechanisms</span><span class="headingEndMark"> — </span>Because BCL-2 overexpression is not sufficient for FL development, other genetic lesions or host factors must be required. The need for additional factors is supported by the observation that BCL-2 transgenic mice develop polyclonal hyperplasia of mature, long lived non-dividing B cells rather than a clonal proliferation resembling FL [<a href="#rid5">5,6</a>]. With time, and analogous to the human disease, a fraction of BCL-2 transgenic mice develops aggressive, clonal large cell lymphomas, which have acquired additional genetic lesions [<a href="#rid29">29</a>]. Clues to mechanisms beyond BCL-2 overexpression that are involved in the development of FL have emerged from deep sequencing of FL genomes and studies of the FL microenvironment. (See <a class="local">'Tumor microenvironment'</a> below.)</p><p class="headingAnchor" id="H26243882"><span class="h2">Other genetic lesions</span><span class="headingEndMark"> — </span>Approximately 90 percent of FL demonstrate genetic alterations in addition to the (14;18) translocation [<a href="#rid1">1</a>]. The most common are loss of 1p, 6q, 10q, and 17p and gains of chromosomes 1, 6p, 7, 8, 12q, X, and 18q/dup. As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>Chromosome 6 – Deletions in the long arm of chromosome 6 occur in approximately 20 percent of cases and have been associated with worse prognosis in multiple studies [<a href="#rid30">30-32</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Chromosome 1 – 1p36, the site of the <em>TNFRSF14</em> gene [<a href="#rid33">33</a>], is affected by deletions, uniparental disomy, and point mutations in a subset of cases, and was previously associated with poor prognosis. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Chromosome 3 – About 5 to 15 percent of FLs have 3q27 abnormalities involving the <em>BCL-6</em> gene, which is commonly involved by genetic aberrations that contribute to the pathogenesis of diffuse large B cell lymphoma [<a href="#rid27">27,28</a>] (see <a class="local">'BCL-2 negative cases'</a> above). By contrast, other proto-oncogenes involved in lymphomagenesis (eg, MYC, cyclin D1) are not involved in FL. </p><p></p><p>Efforts focused on genome sequencing have identified a role for mutation of histone-modifying genes and chromatin-modifying genes in FL. Multiple studies have reported mutations in the following genes (listed in order of decreasing frequency):<em> KMT2D</em>,<em> CREBBP</em>,<em> EZH2</em>,<em> EP300</em>,<em> HIST1H1E</em>,<em> KMT2C</em>,<em> ARID1A</em>, and<em> SMARCA4</em> [<a href="#rid34">34-42</a>]. The mechanism by which these genes promote FL remains to be elucidated, but work looking at the hierarchy of these genetic aberrations has suggested that<em> BCL-2</em> rearrangements,<em> CREBBP</em> mutations, and mutations increasing the function of EZH2 are early "founding" events, and that<em> KMT2D</em> and<em> TNFRSF14</em> mutations occur later in the course, possibly as part of disease progression and/or development of drug resistance [<a href="#rid34">34,37,43</a>]. Disruption of KMT2D perturbs germinal center B cell development and accelerates the onset of germinal center B cell derived lymphomas in <em>BCL-2</em> transgenic mice, confirming that loss of KMT2D activity is lymphomagenic [<a href="#rid44">44</a>]. In addition, several studies have identified recurrent mutations in histone genes [<a href="#rid38">38,39,45,46</a>], reinforcing the notion that abnormalities of chromatin have an important, albeit incompletely understood, role in the pathobiology of FL.</p><p>Other sequencing studies have identified recurrent mutations involving signaling pathways with important roles in B cell biology. One group of recurrent mutations is hypothesized to upregulate mTOR (mammalian target of rapamycin) signaling in FL cells. These mutations, which are found in approximately 15 to 20 percent of cases, may involve genes encoding components of vacuolar H<sup>+</sup>-ATPase, which is known to be necessary for amino acid-induced mTOR activation, or RRAGC, a guanine nucleotide binding protein that also regulates mTOR activation [<a href="#rid47">47</a>]. Somatic mutations also have been identified in a subset of FL in genes that encode components of the B cell receptor (BCR) signaling pathway (eg, <em>BTK</em>, CD79B) [<a href="#rid45">45</a>], which controls many facets of B cell biology, including growth, differentiation, survival, and adhesion or cellular migration. </p><p>Acquired genetic lesions generally increase in number with increasing FL histologic grade, being most numerous with grade 3b histology. Over time, a significant fraction of FL evolves into an aggressive lymphoma, most commonly with a diffuse large cell histology [<a href="#rid48">48</a>]. Morphologic transformation is often associated with disruptive mutations in the tumor suppressor gene <em>TP53</em> on chromosome 17p or the tumor suppressor locus <em>CDKN2A/2B</em> on chromosome 9, which encodes a negative regulator of cell cycle progression and a stabilizer of p53 [<a href="#rid38">38,49-51</a>]. Other common events associated with transformation include amplifications, translocations, and mutations of <em>MYC</em>, an important regulator of cell growth, and loss-of-function mutations in <em>B2M</em> that abolish the expression of major histocompatibility class I antigens, indicating the immune evasion contributes to histologic translocation in some cases [<a href="#rid38">38</a>]. (See  <a class="medical medical_review" href="/z/d/html/4724.html" rel="external">"Histologic transformation of follicular lymphoma", section on 'Cytogenetics'</a>.)</p><p class="headingAnchor" id="H91138016"><span class="h2">Tumor microenvironment</span><span class="headingEndMark"> — </span>The tumor microenvironment, specifically the immunologic microenvironment comprised of T cells and dendritic cells, may influence the development and progression of FL [<a href="#rid52">52-56</a>]. It has been suggested that FL is an immunologically functional disease in which an interaction between the tumor cells and the microenvironment determines overall clinical behavior.</p><p>The role of the microenvironment is supported by gene expression profiling and immunophenotypic studies that have correlated patient survival with types of immune cells that are intermixed with the lymphoma, rather than with the gene expression program of the lymphoma itself [<a href="#rid57">57-60</a>]. Communication between the tumor cells and the microenvironment appears to be bidirectional and likely involves chemokines, chemokine receptors and adhesion molecules, the balance of which determines whether tumor cell growth is stimulated or inhibited [<a href="#rid61">61,62</a>]. Signals from the tumor cells help to determine the composition of the cells in the surrounding area, which in turn support the growth and survival of the malignant cells [<a href="#rid63">63,64</a>].</p><p>Comparisons of gene expression between purified FL cells and normal germinal center B cells have found upregulation of cell cycle mediators, B cell transcription factors, certain cytokines, and genes involved in cell-cell interactions [<a href="#rid65">65</a>]. These differences are consistent with a role for the microenvironment in tumor pathogenesis that requires further study. </p><p>In some instances, mutations involving FL cells may directly influence the nature of their interaction with the microenvironment. FL cells retain expression of surface immunoglobulin (Ig, also known as B cell receptor or BCR), and evidence suggests that signals mediated by the BCR are critical for FL growth and survival. Of interest, the Ig genes in FL in a high fraction of cases acquire mutations that introduce consensus sequences for N-glycosylation, resulting in an unusual post-translational modification in which the added glycan is highly mannosylated [<a href="#rid66">66</a>]. This modified BCR binds a lectin called dendritic cell-specific ICAM3-grabbing nonintegrin (DC-SIGN), which is expressed on infiltrating macrophages and initiates BCR signaling [<a href="#rid67">67,68</a>]. In a second example, a subset of FL has gain-of-function mutations in the <em>CTSS</em> gene, which encodes the protease cathepsin S [<a href="#rid69">69</a>]. Increases in cathepsin S function appear to enhance HLA class II presentation of antigen, leading to increases in the activation of CD4-positive T cells, recruitment of CD4-positive T cells, release of pro-inflammatory cytokines, and growth of FL cells. (See  <a class="medical medical_review" href="/z/d/html/4699.html" rel="external">"Clinical manifestations, pathologic features, diagnosis, and prognosis of follicular lymphoma", section on 'Microenvironment'</a>.)</p><p class="headingAnchor" id="H91138008"><span class="h1">HETEROGENEITY OF FL</span></p><p class="headingAnchor" id="H1322932601"><span class="h2">Spacial and temporal heterogeneity</span><span class="headingEndMark"> — </span>Within an individual, there are differences in the FL tumor cells and tumor environment found at different disease sites at the same time (spacial heterogeneity) and at the same disease site across time (temporal heterogeneity). </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Spacial heterogeneity</strong> – Biopsies of multiple tumor sites reveal genomic differences with varying patterns of somatic mutations and gene expression across sites within an individual [<a href="#rid70">70,71</a>]. While our understanding about the clinical impact of these differences is evolving, some may help explain discordant responses to therapy at different disease sites.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Temporal heterogeneity</strong> – FL tumor cells within individual patients are genetically heterogeneous, with several subpopulations of malignant cells evolving over time [<a href="#rid41">41</a>]. The relative contribution of each subpopulation to the total tumor volume is likely affected by interactions with other subpopulations, the tumor microenvironment, and therapy. This heterogeneity represents genetic variation upon which selection can act and contributes to the development of resistant disease and progression (transformation) to more aggressive disease. (See <a class="local">'Transformation'</a> below.)</p><p></p><p class="headingAnchor" id="H563214448"><span class="h2">Diversity of cases</span><span class="headingEndMark"> — </span>The diagnostic category of FL is heterogeneous in terms of morphology, genetics, and biologic behavior. It is generally unclear how this variation relates to clinical outcome and response to therapy, which constitute areas of ongoing investigation. </p><p>As examples: </p><p class="bulletIndent1"><span class="glyph">●</span>Tumors with <em>EZH2</em> mutations show increased H3K27 trimethylation [<a href="#rid72">72</a>] and have a better prognosis than <em>EZH2</em> wild type FLs [<a href="#rid73">73,74</a>]. The increase in H3K27 trimethylation in <em>EZH2</em> mutated FL is a direct result of gain-of-function mutations in <em>EZH2</em> [<a href="#rid37">37</a>], an insight that has led to use of the EZH2 inhibitor <a class="drug drug_general" data-topicid="126937" href="/z/d/drug information/126937.html" rel="external">tazemetostat</a> for treatment of relapsed/refractory FL with <em>EZH2</em> mutations [<a href="#rid75">75</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>FL that develops in the setting of hepatitis B virus infection is less likely to be associated with the t(14;18) and appears to have a more aggressive clinical course [<a href="#rid76">76</a>]. This subgroup of FL have mutational and gene expression signatures and microenvironmental features that are distinct from FL developing in the absence of hepatitis B virus infection.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Full understanding of the FL microenvironment requires characterization of not only FL cells and reactive immune cells, but also non-hematopoietic cells such as follicular dendritic cells, other fibroblast-derived stromal cells, and blood vessel- and lymphatic vessel-associated cells. Studies using single cell RNA-sequencing have begun to reveal changes in non-hematopoietic cells in the FL microenvironment, a first step in detailing crosstalk between FL cells and non-hematopoietic cells that promotes FL growth and survival [<a href="#rid77">77</a>].</p><p></p><p class="headingAnchor" id="H30617521"><span class="h1">TRANSFORMATION</span><span class="headingEndMark"> — </span>Histologic transformation (HT) refers to the evolution of a clinically indolent non-Hodgkin lymphoma (NHL; eg, FL) to a clinically aggressive NHL (eg, diffuse large B cell lymphoma [DLBCL]) defined as those lymphomas in which survival of the untreated patient is measured in months. This is discussed in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/4724.html" rel="external">"Histologic transformation of follicular lymphoma"</a>.)</p><p class="headingAnchor" id="H26244291"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cell of origin</strong> – Follicular lymphoma (FL) is the second most common histologic subtype of non-Hodgkin lymphoma. The molecular pathogenesis of FL is a complex, multistep process leading to the outgrowth of a malignant clone of germinal B cell origin  (<a class="graphic graphic_figure graphicRef56311" href="/z/d/graphic/56311.html" rel="external">figure 1</a>). While some steps in this pathway have been elucidated, many remain unknown. (See <a class="local">'Cell of origin'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Aberrant BCL-2 expression</strong> – The development of the majority of FL tumors in adults is associated with the overexpression of B cell leukemia/lymphoma 2 (<em>BCL-2</em>) located on chromosome band 18q21. <em>BCL-2</em> is an oncogene that blocks programmed cell death (apoptosis). As such, overexpression results in prolonged cell survival. (See <a class="local">'Aberrant BCL-2 expression'</a> above.)</p><p></p><p class="bulletIndent1">In the vast majority of cases, FL is associated with a translocation between the long arm of chromosome 18, the site of the <em>BCL-2</em> oncogene, and one of the three immunoglobulin (Ig) genes. The most common translocation involves the Ig heavy chain gene resulting in the t(14;18)(q32;q21), found in approximately 85 percent of FL. (See <a class="local">'Translocations involving BCL-2'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong><em>BCL-2</em></strong><strong> negative cases</strong> – Less than 10 percent of FL tumors lack <em>BCL-2</em> translocations and fail to express BCL-2 proteins. BCL-2 negativity is most commonly seen in grade 3b FL, in which the tumor is comprised of solid sheets of centroblasts that nonetheless grow in a follicular pattern. (See <a class="local">'BCL-2 negative cases'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other mechanisms</strong> – BCL-2 overexpression in itself is not sufficient for FL development and other genetic lesions or host factors are required. Many of the complementary mutations involve genes that regulate the epigenome (eg, histone modifications, chromatin structure). Other important factors involve the local host response and tumor microenvironment, and modifications in the B cell receptor that may augment B cell receptor signaling. (See <a class="local">'Other mechanisms'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">World health organization classification of tumours of haematopoietic and lymphoid tissues, revised 4th edition, Swerdlow SH, Campo E, Harris NL, et al. (Eds), IARC, Lyon 2017.</li><li><a class="nounderline abstract_t">Ottensmeier CH, Thompsett AR, Zhu D, et al. Analysis of VH genes in follicular and diffuse lymphoma shows ongoing somatic mutation and multiple isotype transcripts in early disease with changes during disease progression. Blood 1998; 91:4292.</a></li><li><a class="nounderline abstract_t">Raghavan SC, Swanson PC, Wu X, et al. A non-B-DNA structure at the Bcl-2 major breakpoint region is cleaved by the RAG complex. Nature 2004; 428:88.</a></li><li><a class="nounderline abstract_t">Korsmeyer SJ. Bcl-2 initiates a new category of oncogenes: regulators of cell death. Blood 1992; 80:879.</a></li><li><a class="nounderline abstract_t">Nuñez G, Hockenbery D, McDonnell TJ, et al. Bcl-2 maintains B cell memory. Nature 1991; 353:71.</a></li><li><a class="nounderline abstract_t">McDonnell TJ, Deane N, Platt FM, et al. bcl-2-immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation. Cell 1989; 57:79.</a></li><li><a class="nounderline abstract_t">Cory S, Adams JM. The Bcl2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer 2002; 2:647.</a></li><li><a class="nounderline abstract_t">Cory S, Adams JM. Killing cancer cells by flipping the Bcl-2/Bax switch. Cancer Cell 2005; 8:5.</a></li><li><a class="nounderline abstract_t">Boise LH, González-García M, Postema CE, et al. bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 1993; 74:597.</a></li><li><a class="nounderline abstract_t">Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 1993; 74:609.</a></li><li><a class="nounderline abstract_t">Yang E, Korsmeyer SJ. Molecular thanatopsis: a discourse on the BCL2 family and cell death. Blood 1996; 88:386.</a></li><li><a class="nounderline abstract_t">Ghia P, Boussiotis VA, Schultze JL, et al. Unbalanced expression of bcl-2 family proteins in follicular lymphoma: contribution of CD40 signaling in promoting survival. Blood 1998; 91:244.</a></li><li><a class="nounderline abstract_t">Limpens J, de Jong D, van Krieken JH, et al. Bcl-2/JH rearrangements in benign lymphoid tissues with follicular hyperplasia. Oncogene 1991; 6:2271.</a></li><li><a class="nounderline abstract_t">Aster JC, Kobayashi Y, Shiota M, et al. Detection of the t(14;18) at similar frequencies in hyperplastic lymphoid tissues from American and Japanese patients. Am J Pathol 1992; 141:291.</a></li><li><a class="nounderline abstract_t">Limpens J, Stad R, Vos C, et al. Lymphoma-associated translocation t(14;18) in blood B cells of normal individuals. Blood 1995; 85:2528.</a></li><li><a class="nounderline abstract_t">Dölken G, Illerhaus G, Hirt C, Mertelsmann R. BCL-2/JH rearrangements in circulating B cells of healthy blood donors and patients with nonmalignant diseases. J Clin Oncol 1996; 14:1333.</a></li><li><a class="nounderline abstract_t">Roulland S, Navarro JM, Grenot P, et al. Follicular lymphoma-like B cells in healthy individuals: a novel intermediate step in early lymphomagenesis. J Exp Med 2006; 203:2425.</a></li><li><a class="nounderline abstract_t">Roulland S, Kelly RS, Morgado E, et al. t(14;18) Translocation: A predictive blood biomarker for follicular lymphoma. J Clin Oncol 2014; 32:1347.</a></li><li><a class="nounderline abstract_t">Bloomfield CD, Arthur DC, Frizzera G, et al. Nonrandom chromosome abnormalities in lymphoma. Cancer Res 1983; 43:2975.</a></li><li><a class="nounderline abstract_t">Rowley JD. Chromosome studies in the non-Hodgkin's lymphomas: the role of the 14;18 translocation. J Clin Oncol 1988; 6:919.</a></li><li><a class="nounderline abstract_t">Graninger WB, Seto M, Boutain B, et al. Expression of Bcl-2 and Bcl-2-Ig fusion transcripts in normal and neoplastic cells. J Clin Invest 1987; 80:1512.</a></li><li><a class="nounderline abstract_t">Ngan BY, Chen-Levy Z, Weiss LM, et al. Expression in non-Hodgkin's lymphoma of the bcl-2 protein associated with the t(14;18) chromosomal translocation. N Engl J Med 1988; 318:1638.</a></li><li><a class="nounderline abstract_t">Schraders M, de Jong D, Kluin P, et al. Lack of Bcl-2 expression in follicular lymphoma may be caused by mutations in the BCL2 gene or by absence of the t(14;18) translocation. J Pathol 2005; 205:329.</a></li><li><a class="nounderline abstract_t">Katzenberger T, Kalla J, Leich E, et al. A distinctive subtype of t(14;18)-negative nodal follicular non-Hodgkin lymphoma characterized by a predominantly diffuse growth pattern and deletions in the chromosomal region 1p36. Blood 2009; 113:1053.</a></li><li><a class="nounderline abstract_t">Siddiqi IN, Friedman J, Barry-Holson KQ, et al. Characterization of a variant of t(14;18) negative nodal diffuse follicular lymphoma with CD23 expression, 1p36/TNFRSF14 abnormalities, and STAT6 mutations. Mod Pathol 2016; 29:570.</a></li><li><a class="nounderline abstract_t">Ott G, Katzenberger T, Lohr A, et al. Cytomorphologic, immunohistochemical, and cytogenetic profiles of follicular lymphoma: 2 types of follicular lymphoma grade 3. Blood 2002; 99:3806.</a></li><li><a class="nounderline abstract_t">Bosga-Bouwer AG, van Imhoff GW, Boonstra R, et al. Follicular lymphoma grade 3B includes 3 cytogenetically defined subgroups with primary t(14;18), 3q27, or other translocations: t(14;18) and 3q27 are mutually exclusive. Blood 2003; 101:1149.</a></li><li><a class="nounderline abstract_t">Díaz-Alderete A, Doval A, Camacho F, et al. Frequency of BCL2 and BCL6 translocations in follicular lymphoma: relation with histological and clinical features. Leuk Lymphoma 2008; 49:95.</a></li><li><a class="nounderline abstract_t">Ye BH, Lista F, Lo Coco F, et al. Alterations of a zinc finger-encoding gene, BCL-6, in diffuse large-cell lymphoma. Science 1993; 262:747.</a></li><li><a class="nounderline abstract_t">Gaidano G, Ballerini P, Gong JZ, et al. p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 1991; 88:5413.</a></li><li><a class="nounderline abstract_t">Schwaenen C, Viardot A, Berger H, et al. Microarray-based genomic profiling reveals novel genomic aberrations in follicular lymphoma which associate with patient survival and gene expression status. Genes Chromosomes Cancer 2009; 48:39.</a></li><li><a class="nounderline abstract_t">Cheung KJ, Shah SP, Steidl C, et al. Genome-wide profiling of follicular lymphoma by array comparative genomic hybridization reveals prognostically significant DNA copy number imbalances. Blood 2009; 113:137.</a></li><li><a class="nounderline abstract_t">Launay E, Pangault C, Bertrand P, et al. High rate of TNFRSF14 gene alterations related to 1p36 region in de novo follicular lymphoma and impact on prognosis. Leukemia 2012; 26:559.</a></li><li><a class="nounderline abstract_t">Green MR, Gentles AJ, Nair RV, et al. Hierarchy in somatic mutations arising during genomic evolution and progression of follicular lymphoma. Blood 2013; 121:1604.</a></li><li><a class="nounderline abstract_t">Pasqualucci L, Dominguez-Sola D, Chiarenza A, et al. Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature 2011; 471:189.</a></li><li><a class="nounderline abstract_t">Morin RD, Mendez-Lago M, Mungall AJ, et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature 2011; 476:298.</a></li><li><a class="nounderline abstract_t">Bödör C, Grossmann V, Popov N, et al. EZH2 mutations are frequent and represent an early event in follicular lymphoma. Blood 2013; 122:3165.</a></li><li><a class="nounderline abstract_t">Pasqualucci L, Khiabanian H, Fangazio M, et al. Genetics of follicular lymphoma transformation. Cell Rep 2014; 6:130.</a></li><li><a class="nounderline abstract_t">Okosun J, Bödör C, Wang J, et al. Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma. Nat Genet 2014; 46:176.</a></li><li><a class="nounderline abstract_t">Green MR, Kihira S, Liu CL, et al. Mutations in early follicular lymphoma progenitors are associated with suppressed antigen presentation. Proc Natl Acad Sci U S A 2015; 112:E1116.</a></li><li><a class="nounderline abstract_t">Kridel R, Chan FC, Mottok A, et al. Histological Transformation and Progression in Follicular Lymphoma: A Clonal Evolution Study. PLoS Med 2016; 13:e1002197.</a></li><li><a class="nounderline abstract_t">Green MR. Chromatin modifying gene mutations in follicular lymphoma. Blood 2018; 131:595.</a></li><li><a class="nounderline abstract_t">Schmidt J, Ramis-Zaldivar JE, Bonzheim I, et al. CREBBP gene mutations are frequently detected in in situ follicular neoplasia. Blood 2018; 132:2687.</a></li><li><a class="nounderline abstract_t">Zhang J, Dominguez-Sola D, Hussein S, et al. Disruption of KMT2D perturbs germinal center B cell development and promotes lymphomagenesis. Nat Med 2015; 21:1190.</a></li><li><a class="nounderline abstract_t">Krysiak K, Gomez F, White BS, et al. Recurrent somatic mutations affecting B-cell receptor signaling pathway genes in follicular lymphoma. Blood 2017; 129:473.</a></li><li><a class="nounderline abstract_t">Li H, Kaminski MS, Li Y, et al. Mutations in linker histone genes HIST1H1 B, C, D, and E; OCT2 (POU2F2); IRF8; and ARID1A underlying the pathogenesis of follicular lymphoma. Blood 2014; 123:1487.</a></li><li><a class="nounderline abstract_t">Okosun J, Wolfson RL, Wang J, et al. Recurrent mTORC1-activating RRAGC mutations in follicular lymphoma. Nat Genet 2016; 48:183.</a></li><li><a class="nounderline abstract_t">Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84:1361.</a></li><li><a class="nounderline abstract_t">Lo Coco F, Gaidano G, Louie DC, et al. p53 mutations are associated with histologic transformation of follicular lymphoma. Blood 1993; 82:2289.</a></li><li><a class="nounderline abstract_t">Sander CA, Yano T, Clark HM, et al. p53 mutation is associated with progression in follicular lymphomas. Blood 1993; 82:1994.</a></li><li><a class="nounderline abstract_t">O'Shea D, O'Riain C, Taylor C, et al. The presence of TP53 mutation at diagnosis of follicular lymphoma identifies a high-risk group of patients with shortened time to disease progression and poorer overall survival. Blood 2008; 112:3126.</a></li><li><a class="nounderline abstract_t">Bende RJ, Smit LA, van Noesel CJ. Molecular pathways in follicular lymphoma. Leukemia 2007; 21:18.</a></li><li><a class="nounderline abstract_t">de Jong D. Molecular pathogenesis of follicular lymphoma: a cross talk of genetic and immunologic factors. J Clin Oncol 2005; 23:6358.</a></li><li><a class="nounderline abstract_t">Carbone A, Gloghini A, Gruss HJ, Pinto A. CD40 ligand is constitutively expressed in a subset of T cell lymphomas and on the microenvironmental reactive T cells of follicular lymphomas and Hodgkin's disease. Am J Pathol 1995; 147:912.</a></li><li><a class="nounderline abstract_t">Petrasch S, Kosco M, Schmitz J, et al. Follicular dendritic cells in non-Hodgkin-lymphoma express adhesion molecules complementary to ligands on neoplastic B-cells. Br J Haematol 1992; 82:695.</a></li><li><a class="nounderline abstract_t">Lindhout E, Mevissen ML, Kwekkeboom J, et al. Direct evidence that human follicular dendritic cells (FDC) rescue germinal centre B cells from death by apoptosis. Clin Exp Immunol 1993; 91:330.</a></li><li><a class="nounderline abstract_t">Dave SS, Wright G, Tan B, et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 2004; 351:2159.</a></li><li><a class="nounderline abstract_t">Alvaro T, Lejeune M, Salvadó MT, et al. Immunohistochemical patterns of reactive microenvironment are associated with clinicobiologic behavior in follicular lymphoma patients. J Clin Oncol 2006; 24:5350.</a></li><li><a class="nounderline abstract_t">Farinha P, Masoudi H, Skinnider BF, et al. Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). Blood 2005; 106:2169.</a></li><li><a class="nounderline abstract_t">Glas AM, Knoops L, Delahaye L, et al. Gene-expression and immunohistochemical study of specific T-cell subsets and accessory cell types in the transformation and prognosis of follicular lymphoma. J Clin Oncol 2007; 25:390.</a></li><li><a class="nounderline abstract_t">Coupland SE. The challenge of the microenvironment in B-cell lymphomas. Histopathology 2011; 58:69.</a></li><li><a class="nounderline abstract_t">Laurent C, Müller S, Do C, et al. Distribution, function, and prognostic value of cytotoxic T lymphocytes in follicular lymphoma: a 3-D tissue-imaging study. Blood 2011; 118:5371.</a></li><li><a class="nounderline abstract_t">Ansell SM. Malignant B cells at the helm in follicular lymphoma. J Clin Oncol 2013; 31:2641.</a></li><li><a class="nounderline abstract_t">Kiaii S, Clear AJ, Ramsay AG, et al. Follicular lymphoma cells induce changes in T-cell gene expression and function: potential impact on survival and risk of transformation. J Clin Oncol 2013; 31:2654.</a></li><li><a class="nounderline abstract_t">Husson H, Carideo EG, Neuberg D, et al. Gene expression profiling of follicular lymphoma and normal germinal center B cells using cDNA arrays. Blood 2002; 99:282.</a></li><li><a class="nounderline abstract_t">Küppers R, Stevenson FK. Critical influences on the pathogenesis of follicular lymphoma. Blood 2018; 131:2297.</a></li><li><a class="nounderline abstract_t">Amin R, Mourcin F, Uhel F, et al. DC-SIGN-expressing macrophages trigger activation of mannosylated IgM B-cell receptor in follicular lymphoma. Blood 2015; 126:1911.</a></li><li><a class="nounderline abstract_t">Linley A, Krysov S, Ponzoni M, et al. Lectin binding to surface Ig variable regions provides a universal persistent activating signal for follicular lymphoma cells. Blood 2015; 126:1902.</a></li><li><a class="nounderline abstract_t">Bararia D, Hildebrand JA, Stolz S, et al. Cathepsin S Alterations Induce a Tumor-Promoting Immune Microenvironment in Follicular Lymphoma. Cell Rep 2020; 31:107522.</a></li><li><a class="nounderline abstract_t">Haebe S, Shree T, Sathe A, et al. Single-cell analysis can define distinct evolution of tumor sites in follicular lymphoma. Blood 2021; 137:2869.</a></li><li><a class="nounderline abstract_t">Araf S, Wang J, Korfi K, et al. Genomic profiling reveals spatial intra-tumor heterogeneity in follicular lymphoma. Leukemia 2018; 32:1261.</a></li><li><a class="nounderline abstract_t">Huet S, Xerri L, Tesson B, et al. EZH2 alterations in follicular lymphoma: biological and clinical correlations. Blood Cancer J 2017; 7:e555.</a></li><li><a class="nounderline abstract_t">Pastore A, Jurinovic V, Kridel R, et al. Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry. Lancet Oncol 2015; 16:1111.</a></li><li><a class="nounderline abstract_t">Makita S, Tobinai K. Targeting EZH2 with tazemetostat. Lancet Oncol 2018; 19:586.</a></li><li><a class="nounderline abstract_t">Italiano A, Soria JC, Toulmonde M, et al. Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study. Lancet Oncol 2018; 19:649.</a></li><li><a class="nounderline abstract_t">Ren W, Wang X, Yang M, et al. Distinct clinical and genetic features of hepatitis B virus-associated follicular lymphoma in Chinese patients. Blood Adv 2022; 6:2731.</a></li><li><a class="nounderline abstract_t">Abe Y, Sakata-Yanagimoto M, Fujisawa M, et al. A single-cell atlas of non-haematopoietic cells in human lymph nodes and lymphoma reveals a landscape of stromal remodelling. Nat Cell Biol 2022; 24:565.</a></li></ol></div><div id="topicVersionRevision">Topic 16646 Version 19.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : World health organization classification of tumours of haematopoietic and lymphoid tissues, revised 4th edition, Swerdlow SH, Campo E, Harris NL, et al. (Eds), IARC, Lyon 2017.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9596678" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Analysis of VH genes in follicular and diffuse lymphoma shows ongoing somatic mutation and multiple isotype transcripts in early disease with changes during disease progression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14999286" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : A non-B-DNA structure at the Bcl-2 major breakpoint region is cleaved by the RAG complex.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1498330" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Bcl-2 initiates a new category of oncogenes: regulators of cell death.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1908951" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Bcl-2 maintains B cell memory.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2649247" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : bcl-2-immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12209154" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : The Bcl2 family: regulators of the cellular life-or-death switch.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16023593" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Killing cancer cells by flipping the Bcl-2/Bax switch.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8358789" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8358790" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8695785" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Molecular thanatopsis: a discourse on the BCL2 family and cell death.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9414291" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Unbalanced expression of bcl-2 family proteins in follicular lymphoma: contribution of CD40 signaling in promoting survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1766674" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Bcl-2/JH rearrangements in benign lymphoid tissues with follicular hyperplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1497088" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Detection of the t(14;18) at similar frequencies in hyperplastic lymphoid tissues from American and Japanese patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7727781" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Lymphoma-associated translocation t(14;18) in blood B cells of normal individuals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8648392" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : BCL-2/JH rearrangements in circulating B cells of healthy blood donors and patients with nonmalignant diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17043145" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Follicular lymphoma-like B cells in healthy individuals: a novel intermediate step in early lymphomagenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24687831" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : t(14;18) Translocation: A predictive blood biomarker for follicular lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6850608" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Nonrandom chromosome abnormalities in lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3284977" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Chromosome studies in the non-Hodgkin's lymphomas: the role of the 14;18 translocation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3500184" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Expression of Bcl-2 and Bcl-2-Ig fusion transcripts in normal and neoplastic cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3287162" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Expression in non-Hodgkin's lymphoma of the bcl-2 protein associated with the t(14;18) chromosomal translocation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15682435" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Lack of Bcl-2 expression in follicular lymphoma may be caused by mutations in the BCL2 gene or by absence of the t(14;18) translocation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18978208" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : A distinctive subtype of t(14;18)-negative nodal follicular non-Hodgkin lymphoma characterized by a predominantly diffuse growth pattern and deletions in the chromosomal region 1p36.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26965583" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Characterization of a variant of t(14;18) negative nodal diffuse follicular lymphoma with CD23 expression, 1p36/TNFRSF14 abnormalities, and STAT6 mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11986240" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Cytomorphologic, immunohistochemical, and cytogenetic profiles of follicular lymphoma: 2 types of follicular lymphoma grade 3.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12529293" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Follicular lymphoma grade 3B includes 3 cytogenetically defined subgroups with primary t(14;18), 3q27, or other translocations: t(14;18) and 3q27 are mutually exclusive.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18203018" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Frequency of BCL2 and BCL6 translocations in follicular lymphoma: relation with histological and clinical features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8235596" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Alterations of a zinc finger-encoding gene, BCL-6, in diffuse large-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2052620" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18828156" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Microarray-based genomic profiling reveals novel genomic aberrations in follicular lymphoma which associate with patient survival and gene expression status.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18703704" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Genome-wide profiling of follicular lymphoma by array comparative genomic hybridization reveals prognostically significant DNA copy number imbalances.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21941365" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : High rate of TNFRSF14 gene alterations related to 1p36 region in de novo follicular lymphoma and impact on prognosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23297126" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Hierarchy in somatic mutations arising during genomic evolution and progression of follicular lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21390126" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Inactivating mutations of acetyltransferase genes in B-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21796119" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24052547" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : EZH2 mutations are frequent and represent an early event in follicular lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24388756" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Genetics of follicular lymphoma transformation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24362818" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25713363" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Mutations in early follicular lymphoma progenitors are associated with suppressed antigen presentation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27959929" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Histological Transformation and Progression in Follicular Lymphoma: A Clonal Evolution Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29158360" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Chromatin modifying gene mutations in follicular lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30401710" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : CREBBP gene mutations are frequently detected in in situ follicular neoplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26366712" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Disruption of KMT2D perturbs germinal center B cell development and promotes lymphomagenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28064239" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Recurrent somatic mutations affecting B-cell receptor signaling pathway genes in follicular lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24435047" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Mutations in linker histone genes HIST1H1 B, C, D, and E; OCT2 (POU2F2); IRF8; and ARID1A underlying the pathogenesis of follicular lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26691987" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Recurrent mTORC1-activating RRAGC mutations in follicular lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8068936" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8400281" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : p53 mutations are associated with histologic transformation of follicular lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8400252" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : p53 mutation is associated with progression in follicular lymphomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18628487" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : The presence of TP53 mutation at diagnosis of follicular lymphoma identifies a high-risk group of patients with shortened time to disease progression and poorer overall survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17039231" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Molecular pathways in follicular lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16155020" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Molecular pathogenesis of follicular lymphoma: a cross talk of genetic and immunologic factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7573367" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : CD40 ligand is constitutively expressed in a subset of T cell lymphomas and on the microenvironmental reactive T cells of follicular lymphomas and Hodgkin's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1482656" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Follicular dendritic cells in non-Hodgkin-lymphoma express adhesion molecules complementary to ligands on neoplastic B-cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8428399" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Direct evidence that human follicular dendritic cells (FDC) rescue germinal centre B cells from death by apoptosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15548776" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17135637" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Immunohistochemical patterns of reactive microenvironment are associated with clinicobiologic behavior in follicular lymphoma patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15933054" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17200149" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Gene-expression and immunohistochemical study of specific T-cell subsets and accessory cell types in the transformation and prognosis of follicular lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21261684" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : The challenge of the microenvironment in B-cell lymphomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21856865" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Distribution, function, and prognostic value of cytotoxic T lymphocytes in follicular lymphoma: a 3-D tissue-imaging study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23775955" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Malignant B cells at the helm in follicular lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23775959" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Follicular lymphoma cells induce changes in T-cell gene expression and function: potential impact on survival and risk of transformation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11756183" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Gene expression profiling of follicular lymphoma and normal germinal center B cells using cDNA arrays.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29666116" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Critical influences on the pathogenesis of follicular lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26272216" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : DC-SIGN-expressing macrophages trigger activation of mannosylated IgM B-cell receptor in follicular lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26194765" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Lectin binding to surface Ig variable regions provides a universal persistent activating signal for follicular lymphoma cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32330423" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Cathepsin S Alterations Induce a Tumor-Promoting Immune Microenvironment in Follicular Lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33728464" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Single-cell analysis can define distinct evolution of tumor sites in follicular lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29568095" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Genomic profiling reveals spatial intra-tumor heterogeneity in follicular lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28430172" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : EZH2 alterations in follicular lymphoma: biological and clinical correlations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26256760" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29650364" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Targeting EZH2 with tazemetostat.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29650362" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35030632" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Distinct clinical and genetic features of hepatitis B virus-associated follicular lymphoma in Chinese patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35332263" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : A single-cell atlas of non-haematopoietic cells in human lymph nodes and lymphoma reveals a landscape of stromal remodelling.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
